Product logins

Find logins to all Clarivate products below.


Juliane Ray

General Manager, Medtech

Juliane Ray 是 Clarivate 医疗技术战略全球负责人,她能将有专业知识的人才、工作模式与能带来商业成功的方式相链接。 In this role, she connects people with intelligence, expertise and workflow tools to bring commercially successful treatments to patients faster and enable teams to make decisions with speed and confidence, from strategy through research and development and, ultimately, commercial execution.

Juliane has held several global leadership roles in the medical device and technology industries. She began her career in consulting at Deloitte and ZS Associates, where she collaborated with life sciences executives on commercial strategy. She spent more than 10 years leading marketing, strategy and operations teams at Cardiovascular Systems Inc (acquired by Abbott Vascular), American Medical Systems (acquired by Boson Scientific) and Landauer (acquired by Danaher) before joining Veeva as Vice President of Medtech Commercial Strategy in 2021 and joining Clarivate in 2024.

Juliane holds an MBA from the University of Virginia (Darden School of Business) and a BA in economics and international studies from Macalester College. She also serves as Board Chair at the Jungle, a nonprofit theater in her home city of Minneapolis, Minnesota.

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全